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Abstract
BACKGROUND—Similar to volatile anesthetics, the anesthetic noble gas xenon protects the heart
from ischemia/reperfusion injury, but the mechanisms responsible for this phenomenon are not fully
understood. We tested the hypothesis that xenon-induced cardioprotection is mediated by prosurvival
signaling kinases that target mitochondria.
METHODS—Male Wistar rats instrumented for hemodynamic measurements were subjected to a
30 min left anterior descending coronary artery occlusion and 2 h reperfusion. Rats were randomly
assigned to receive 70% nitrogen/30% oxygen (control) or three 5-min cycles of 70% xenon/30%
oxygen interspersed with the oxygen/nitrogen mixture administered for 5 min followed by a 15 min
memory period. Myocardial infarct size was measured using triphenyltetrazolium staining.
Additional hearts from control and xenon-pretreated rats were excised for Western blotting of Akt
and glycogen synthase kinase 3 β (GSK-3β) phosphorylation and isolation of mitochondria.
Mitochondrial oxygen consumption before and after hypoxia/reoxygenation and mitochondrial
permeability transition pore opening were determined.
RESULTS—Xenon significantly (P < 0.05) reduced myocardial infarct size compared with control
(32 ± 4 and 59% ± 4% of the left ventricular area at risk; mean ± SD) and enhanced phosphorylation
of Akt and GSK-3β. Xenon pretreatment preserved state 3 respiration of isolated mitochondria
compared with the results obtained in the absence of the gas. The Ca2+ concentration required to
induce mitochondrial membrane depolarization was larger in the presence compared with the absence
of xenon pretreatment (78 ± 17 and 56 ± 17 μM, respectively). The phosphoinositol-3-kinase-kinase
inhibitor wortmannin blocked the effect of xenon on infarct size and respiration.
CONCLUSIONS—These results indicate that xenon preconditioning reduces myocardial infarct
size, phosphorylates Akt, and GSK-3β, preserves mitochondrial function, and inhibits Ca2+-induced
mitochondrial permeability transition pore opening. These data suggest that xenon-induced
cardioprotection occurs because of activation of prosurvival signaling that targets mitochondria and
renders them less vulnerable to ischemia-reperfusion injury.
Brief exposure to a volatile anesthetic before prolonged coronary artery occlusion and
reperfusion protects the myocardium from irreversible ischemic injury termed “anesthetic
preconditioning,” APC.1-3 Brief exposure to the anesthetic noble gas xenon also causes
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cardio-4 and neuroprotection.5 The underlying mechanisms responsible for xenon-induced
cardioprotection have been incompletely characterized. Xenon stimulated several important
intracellular prosurvival signaling kinases implicated in cardioprotection, including protein
kinase C (PKC)-ε,4,6 p38 mitogen-activated protein kinase (MAPK),4 MAPK-activated
protein kinase-2,7 heat-shock protein 27,7 and extracellular signal-regulated kinases 1/2.8
The mitochondrial permeability transition pore (mPTP) seems to be an important end-effector
of endogenous cardioprotective signaling. The mPTP plays an essential role in necrosis and
apoptosis after prolonged ischemia and reperfusion.9 Feng et al.10 reported that
phosphorylation of Akt (protein kinase B) and glycogen synthase kinase 3 β (GSK-3β) by
isoflurane prevented mPTP opening and thereby inhibited cell death in ischemia/reperfusion
injury. Prevention of mPTP opening has been shown to limit mitochondrial depolarization,
preserve mitochondrial function, and prevent the initiation of cell death. Bioenergetics of
isolated cardiac mitochondria obtained from isoflurane-preconditioned rats was better
preserved after hypoxia compared with those that had not been exposed to the volatile
anesthetic.11 In the current investigation, we tested the hypothesis that xenon produces
cardioprotection in rat myocardium by phosphorylating Akt and GSK-3β, preventing mPTP
opening, and protecting mitochondrial bioenergetics.
METHODS
All experiments conducted in the current investigation were approved by the Animal Use and
Care Committee of the Medical College of Wisconsin, Milwaukee, Wisconsin. Furthermore,
all experiments conformed to the Guide for Care and Use of Laboratory Animals published
by the United States National Institutes of Health.
General Preparation and Experimental Protocol
Male Wistar rats (weight, 280−340 g) were anesthetized with sodium thiobutabarbital (Inactin,
150 mg/kg administered intraperitoneally). A tracheostomy was performed and the trachea was
cannulated. The lungs of each rat were ventilated with a 70% nitrogen/30% oxygen mixture.
Heparin-filled catheters were inserted into the right jugular vein and the right carotid artery for
fluid administration and measurement of arterial blood pressure, respectively. A left
thoracotomy was performed. The proximal left anterior descending coronary artery (LAD) was
identified, and a polypropylene ligature was placed around this vessel. The ends of the suture
were threaded through a propylene tube to form a snare. Coronary artery occlusion was
produced by clamping the snare and was verified by the presence of epicardial cyanosis in the
ischemic zone. After 30 min occlusion, reperfusion was achieved by loosening the snare and
confirmed by observing an epicardial hyperemic response. Hemodynamic data were
continuously recorded using a computer interfaced with an analog-to-digital converter. All rats
were subjected to a 30 min LAD occlusion and 2 h reperfusion. Rats were randomly assigned
to 4 groups. One group of rats received no interventions before LAD occlusion and reperfusion.
A second group of rats received 3 cycles of 70% xenon/30% oxygen administered for 5 min
periods interspersed with 5 min intervals 70% nitrogen/30% oxygen following by a final 15
min interval (memory period in order to allow complete washout of xenon) of 70% nitrogen/
30% oxygen before LAD occlusion and reperfusion (Fig. 1). Two additional experimental
groups received the phosphoinositol-3-kinase (PI3K) inhibitor wortmannin (0.6 mg/kg) in the
absence and presence of xenon after the animals were anesthetized. The drug vehicle alone
(dimethyl sulfoxide 0.08 mL/kg) was also tested and did not exhibit any significant effect.
Measurement of Myocardial Infarct Size
Myocardial infarct size was determined as previously described.12 Briefly, after 120 min
reperfusion, the proximal LAD was reoccluded, and patent blue dye was injected IV. The heart
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was excised, and the left ventricle (LV) was cut into 5 or 6 cross-sectional pieces. The LV area
at risk for infarction was obtained by removing normal LV area (blue-stained). The area at risk
was incubated at 37°C for 15 min in 1% 2,3,5-triphenyltetrazolium chloride in 0.1 M phosphate
buffer adjusted to pH 7.4. After overnight storage in 10% formaldehyde, the infarcted
(unstained) tissue was carefully separated from the area at risk and weighed. Infarct size was
expressed as a percentage of the LV area at risk.
Preparation of Cardiac Mitochondria
Mitochondria were isolated according to the previously reported procedure.11 Rat hearts, as
described above, with or without xenon pretreatment and with and without wortmannin were
quickly excised (see experimental protocols in Fig. 1). The atrium and right ventricle were
removed, and LV was minced into 1.0 mm pieces in isolation buffer (50 mM sucrose, 200 mM
mannitol, 5 mM KH2PO4, 1 mM ethylene glycol-bis(β-aminoethylether)-N,N,N’,N’-
tetraacetic acid [EGTA], 5 mM 3-(N-morpholino)propanesulfonic acid, and 0.1% bovine
serum albumin [BSA], pH 7.3). The ventricular myocardium was homogenized twice for 5 s
with T 25 disperser (IKA-Werke, Staufen, Germany), and the homogenate was centrifuged at
800g. The supernatant was saved, the pellet re-homogenized for 5 s, and the homogenate
centrifuged at 800g. This second supernatant was combined with the saved first supernatant,
and the pellet was homogenized with Potter-Elvehjem grinder (Weaton, Millville, NJ) in BSA-
free isolation buffer containing 4.8 IU/mL protease VIII (Sigma-Aldrich, St. Louis, MO). The
combined supernatant and homogenized pellet were centrifuged at 6000g, and the resulting
pellets were purified in isolation buffer by homogenization with Potter-Elvehjem grinder and
differential centrifugation at 800 and 6000g. The mitochondrial pellet was resuspended in
isolation buffer without EGTA, stored on ice and used for experiments within 4 h. Protein
concentration was determined by the modified Lowry assay kit (Bio-Rad, Hercules, CA). All
procedures were performed on ice.
Measurement of Mitochondrial Oxygen Consumption
Mitochondrial oxygen consumption was measured with an oxygen electrode (Hansatech
Instruments, Norfolk, UK) at 30°C in mitochondrial respiration buffer (130 mM KCl, 5 mM
KH2PO4, 20 mM 3-(N-morpholino) propanesulfonic acid, 2.5 mM EGTA, 1 μM Na4P2O7,
and 0.1% BSA, pH 7.4) containing mitochondria at a final concentration of 1 mg protein/mL.
State 2 respiration was initiated with 5 mM pyruvate and 5 mM malate as substrates. The
adenosine diphosphate (ADP)-stimulated respiration (state 3) was measured in the presence of
250 μM ADP, and the ADP-independent respiration (state 4) was monitored after all ADP was
consumed. Hypoxia was reached within 5 min as mitochondria consumed all available oxygen
in the chamber. Throughout the hypoxic interval (20 min), the oxygen concentration within
the closed chamber containing the mitochondrial suspension was zero. After the hypoxic
interval, the chamber containing mitochondrial suspension was opened to room air to initiate
a 10 min reoxygenation period. Oxygen consumption in the chamber was measured again as
described above. The respiratory control ratio (RCR), defined as the ratio of oxygen
consumption during state 3 to state 4 (a measure for the coupling of adenosine triphosphate
synthesis to respiration), was calculated to evaluate the degree of mitochondrial damage before
and after exposure to 15 min hypoxia and 10 min reoxygenation.
Measurement of Ca2+-Induced mPTP Opening
Opening of the mPTP was assessed by measurement of isolated mitochondrial membrane
potential (Δϕm) with fluorescent indicator rhodamine 123 (Invitrogen, Carlsbad, CA).
Mitochondria at a final concentration of 1 mg protein/mL were added into buffer containing
220 mM sucrose, 10 mM KH2PO4, 10 mM HEPES, 50 nM Rhodamine 123, and 5 mM pyruvate
and malate. The fluorescence was recorded using a spectrofluorometer (Photon Technology
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International, Birmingham, NJ) at excitation and emission wavelengths of 503 nm and 527
nm, respectively. After an equilibration period during state 2 respiration, 5 μM aliquots of
CaCl2 were sequentially added repeatedly at 60 s intervals until Δϕm was dissipated, indicated
by an increase in fluorescence. Specificity for mPTP opening was tested by repeating the
experiment in the presence of the mPTP inhibitor cyclosporine A (1 μM).13 The amount of
Ca2+ required to induce Δϕm dissipation was used as the variable to evaluate the effect of
xenon preconditioning on mPTP opening.
Western Blotting
Western blotting was performed as described previously.14 LV tissue samples were collected
from the control and xenon-treated rats after a 15 min memory period (see experimental
protocols, Fig. 1), immediately frozen in liquid nitrogen, and stored at −80°C. Tissue was
homogenized with T 25 disperser in ice-cold lysis buffer containing 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Nonidet P40, 2.5 mM Na4P2O7, 1 mM Na3VO4, 1 tablet/10 mL
protease inhibitor cocktail “complete mini” (Roche, Indianapolis, IN), and 20 mM Tris/HCl,
pH 7.4. The homogenate was centrifuged at 10,000g for 15 min at 4°C and the protein
concentration was determined in the supernatant by the modified Lowry assay kit. Equivalent
amounts of protein (50 μg) samples were mixed with loading buffer and heated at 95°C. All
samples were separated on a 4%−15% polyacrylamide gel (Bio-Rad) and electrophoretically
transferred to a nitrocellulose membrane (Bio-Rad). After blocking with 5% milk in Tris-
buffered saline containing 0.1% Tween-20 and 50 mM NaF, nitrocellulose membranes were
incubated overnight at 4°C in 0.1% Tween-20 containing 5% milk and a 1:1000 dilution of
monoclonal antibody against Ser 473 of phospho-Akt or Ser 9 of phospo-GSK-3β (Cell
Signaling Technology, Beverly, MA). Membranes were washed 3 times with 0.1% Tween-20
for 5 min and incubated with a 1:10,000 dilution of horseradish peroxidase-labeled antimouse
immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA) in 0.1% Tween-20 containing
5% milk. Bound antibody was detected by enhanced chemiluminescence (Amersham
Pharmacia, Piscataway, NJ) on radiographic film. Ponceau 0.1% (Sigma-Aldrich, St. Lois,
MO) staining of nitrocellulose membranes was used to verify equal protein loading. To
determine total Akt and GSK-3β, the membrane was stripped with restore stripping buffer
(Pierce, Rockford, IL) and re-probed with polyclonal goat Akt or GSK-3β antibody (Santa
Cruz Biotechnology). Quantitative analysis of the band densities was performed using
AlphaImager 2000 software (Alpha Innotech Corporation, San Leandro, CA). Band densities
obtained from phosphorylated proteins were normalized against the concentrations of total Akt
or GSK-3β.
Statistical Analysis
The effect of xenon preconditioning on hemodynamics and mitochondrial bioenergetics were
assessed using one-way analysis of variance with Scheffé post hoc test. Comparisons of
myocardial infarct size, Akt and GSK-3β phosphorylations and total amount of calcium to open
mPTP among experimental groups were made using Student's t-test for unpaired data. Changes
were considered statistically significant when P < 0.05. All data are expressed as mean ± SD
(SD), with “n” representing the number of experiments.
RESULTS
No significant (P < 0.05) differences in baseline hemodynamics were observed among groups
(Table 1). A decrease in heart rate was observed in rats receiving xenon during LAD occlusion
compared with those that did not. Coronary artery occlusion and reperfusion decreased heart
rate, mean arterial blood pressure, and rate-pressure product in all groups. Heart rate was slower
in xenon-pretreated compared with control rats 60 and 120 min after reperfusion. No
differences in mean arterial blood pressure were observed among groups. Rate-pressure
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product was also lower in rats receiving xenon compared with control 60 min after reperfusion.
Body weight, LV mass, area at risk weight, and the ratio of area at risk to LV mass were similar
among groups (data not shown). Xenon preconditioning reduced myocardial infarct size
compared with control (32 ± 4 and 59% ± 4% of the LV area at the risk, respectively; n = 6
per group), and this decrease was reversed by PI3K inhibitor wortmannin (58% ± 5%).
Wortmannin alone did not have any significant effect on the infarct size (60% ± 6%).
Typical chart recordings of oxygen consumption in isolated rat mitochondria before and after
hypoxia/reoxygenation are depicted in Figure 2. After hypoxic stress, the ADP-stimulated
oxygen consumption and ADP-independent oxygen consumption (state 3 and 4 respiration,
respectively) in isolated mitochondria were preserved in xenon-pretreated (solid circle)
compared to control rats (open circle). Distinct respiration states (indicating coupled
mitochondria) were also maintained after xenon preconditioning compared with control.
Alteration in the rate of state 3 and state 4 respiration and RCR before (baseline) and after
hypoxic stress are illustrated in Figure 3. Under baseline conditions, no differences in state 3
and state 4 respiration and RCR were observed in isolated mitochondria among groups (n = 7
each). After exposure to hypoxia/reoxygenation, state 3 respiration in control mitochondria
decelerated (82 ± 9 to 51 ± 15 nmol O2 · min−1 · mg protein−1, before and after hypoxia,
respectively), producing a lower RCR (3.3 ± 0.9 and 1.8 ± 0.5, before and after hypoxia,
respectively). In contrast, state 3 respiration and RCR in mitochondria isolated from xenon-
preconditioned rats were similar before (79 ± 8 nmol O2 · min−1 · mg protein−1 and 3.2 ± 0.8,
respectively) compared with after exposure (77 ± 14 nmol O2 · min−1 · mg protein−1 and 3.1
± 0.7, respectively) to hypoxia. The presence of wortmannin during xenon exposure prevented
the xenon-induced preservation of RCR (1.4 ± 0.5, not shown). These data suggest that xenon
preconditioning protects mitochondria against hypoxia/reoxygenation injury.
Typical changes in Δϕm after sequential aliquots of CaCl2 (5 μM, arrow) in control (open
circle) and xenon-preconditioned (solid circle) rats and in the presence of cyclosporine A are
illustrated in Figure 4A. Ca2+ is initially taken up into the mitochondrial matrix and Δϕm
remains unaffected. Excess of Ca2+ loading produces sudden Δϕm depolarization, indicating
the release of Ca2+ into the medium as a result of mPTP opening. More Ca2+ was required to
initiate Δϕm depolarization in xenon-preconditioned compared with control mitochondria. In
the presence of cyclosporine A, Δϕm dissipation was not detectable, verifying that
depolarization was due to mPTP opening. The Ca2+ concentration required to induce Δϕm
depolarization was larger in xenon-preconditioned compared with control mitochondria (Fig.
4B; 78 ± 17 and 56 ± 17 μM, respectively; n = 6 per group).
The effect of xenon preconditioning on phosphorylation of Akt (n = 4) and GSK-3β (n = 4)
are illustrated in Figure 5. Total Akt and GSK-3β expression were comparable among groups.
Xenon preconditioning increased the phosphorylation of Akt at Ser 473 (Fig. 5A) and
GSK-3β at Ser 9 (Fig. 5B). Densities of p-Akt and p-GSK-3β relative to total Akt and
GSK-3β were greater in xenon-preconditioned compared with control myocardium (Fig. 5C).
DISCUSSION
The current results confirm previous findings that brief exposure to 70% xenon before coronary
artery occlusion and reperfusion reduces myocardial infarct size in rats in vivo.4,6,8 In the
present study, cardioprotection by xenon against ischemia-induced damage was obtained at
the nonanesthetic dose of 70%. The minimum alveolar concentration value for xenon in rats
is significantly higher compared to humans and has been reported to be 1.61 atmosphere15
compared to about 70% in humans.16 Thus, if anesthetic efficacy is used as a measure, and if
xenon at 1.61 atm in rats is equivalent to xenon at 70% in humans, then 70% xenon in rats
would correspond to about 30% in humans. Xenon is essentially chemically inert, but induced
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dipoles in its large electron field allow xenon to interact with amphiphilic domains of proteins
and membrane.17 The precise mechanism by which this interaction produces selective
biological effects remains unknown. Xenon produces minimal hemodynamic effects and may
be especially suitable as an inhaled anesthetic for patients with cardiac risk factors undergoing
surgery.18-20 Xenon and volatile anesthetics exert very similar actions on cardiac and neuronal
signal transaction. The current results extend this observation by implicating prosurvival
signaling kinases (Akt, GSK-3β) in xenon preconditioning that have been shown to mediate
cardioprotection by volatile anesthetics.1-3
Mitochondria play an essential role in the development of ischemia and reperfusion injury, but
also in the protection against it. Recently, we reported that isoflurane preconditioning elicits
partial mitochondrial uncoupling, an action that preserves cell viability during the conditions
of metabolic challenge.11 The current results are supported, to some degree, by these previous
findings. However, in the current study the RCR (a measure of mitochondrial coupling) under
baseline condition was not altered in isolated ventricular mitochondria obtained from xenon-
preconditioned rats. Since mitochondrial uncoupling was not observed in xenon-
preconditioned mitochondria, this phenomenon may not be required for protection of
mitochondria, as xenon exposure still preserved mitochondrial function after hypoxia and
reoxygenation. Opening of mPTP contributes to cell death after ischemia/reperfusion injury.
21-22 Ischemic and anesthetic pre- and postconditioning have been shown to inhibit mPTP
opening.23-25 The current results indicate brief, intermittent xenon exposure attenuated Ca2+-
induced mPTP opening in vitro, as demonstrated by larger amounts of Ca2+ required for
dissipating Δϕm. Collectively, these data suggest that cardioprotection by xenon occurs as a
consequence of a mechanism inherent to the mitochondria, independent of the cytosolic
environment.
The current findings strongly suggest that xenon preconditioning phosphorylates two key
proteins known to modulate the transition state of mPTP. Activation of several endogenous
cardioprotective signaling pathways has been shown to be essential for xenon-induced
cardioprotection.4,6-8 Interestingly, other noble gases without anesthetic properties have also
recently been demonstrated to produce cardioprotection by activating prosurvival signaling
kinases and inhibiting mPTP opening in rabbits.26 The exact manner in which xenon and other
anesthetic stimuli activate prosurvival signaling pathways remains unknown. The involvement
of G protein-coupled receptors has been discussed27 as well as reactive oxygen species (ROS)
derived from mitochondria.28 The downstream targets of many of these enzymes have yet to
be fully characterized. Nevertheless, the participation of several prosurvival kinases in
protection of the myocardium against ischemia has been well described. Activation of PI3K,
which is blocked by wortmannin, leads to sequential phosphorylation and thereby activation
of phosphoinositide-dependent kinase −1 and Akt.29 PI3K and phosphoinositide-dependent
kinase −1may also activate PKC.30 Activated Akt stimulates the activity of several
antiapoptotic proteins, such as Bcl-2, endothelial nitric oxide synthase and Mdm2,30 and also
inhibits GSK 3β. GSK-3β mediates the convergence of intracellular prosurvival signaling
kinases, including Akt, mammalian target of rapamycin, 70 kDa ribosomal s6 kinase, PKC and
protein kinase.31 The activity of GSK-3β is inhibited by phosphorylation through activated
Akt,32 and inhibition of GSK-3β prevents opening of mPTP.33 The precise mechanism by
which phosphorylation of GSK-3β deactivates the enzyme and prevents mPTP opening during
reperfusion remains unclear. Nevertheless, our results demonstrating that xenon
preconditioning increases phosphorylation of Akt and GSK-3β may represent a link between
the activation of these enzymes and protection of mitochondrial function by rendering mPTP
less susceptible to Ca2+-induced opening. Our findings, that PI3K-inhibitor wortmannin not
only blocked reduction of infarct size but also reversed conservation of mitochondrial RCR,
are in agreement with this assumption.
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Xenon has been shown to exert substantial organo-protective properties in the brain and in the
heart.34 To our knowledge the protective of effect of xenon on other organs has not been studied
yet. Considering some of the mechanistic similarities with ischemic preconditioning, it is
feasible to assume that other organs, such as the kidney, may also be protected by xenon from
ischemic injury. However, it seems that some of the xenon-induced effects are organ-specific,
for example the antagonism of aspartate receptors35 in neurons. Thus, ultimately only future
experiments will be able to answer the question whether other organs besides brain and heart
are protected by xenon.
Xenon-induced, volatile anesthetic-induced and ischemic preconditioning have all been shown
to produce a strong cardioprotective effect in the rat heart in vivo, and overall, the mechanistic
similarities of those protective strategies are striking. Particularly, prosurvival signaling
pathways are shared by all of these strategies, including the involvement of PKC isoforms and
downstream kinases, such as p38 and ERK1/2 MAPK. Nevertheless, little is known specifically
about the mechanism of xenon preconditioning, and some differences have been pointed out.
For example, c-Jun N-terminal kinase MAPK activation has been shown to play a role in
ischemic preconditioning,36 but not in xenon-induced preconditioning,8 and its role in APC
has not been studied. A microarray study revealed differences between APC versus ischemic
preconditioning in transcripts predominantly related to biosynthesis and apoptosis where
ischemic preconditioning elicited a postischemic gene expression profile closer to unprotected
myocardium than preconditioning with a volatile anesthetic.37 However, a similar study has
not been performed for xenon-induced preconditioning. In our study, we confirmed the
participation of signaling kinases similarly to ischemic and APC, but also found subtle
differences in the effect of the preconditioning agent on mitochondrial function as described
above. This is interesting since a direct effect of the preconditioning agent on mitochondria
has been suggested to be involved in the triggering of prosurvival pathways, for example
through ROS.38 Therefore, future studies will be needed to further investigate the direct effect
of xenon on mitochondrial bioenergetics, including ROS production. However, mitochondrial
function remained preserved after ischemic stress on mitochondria isolated from xenon-
preconditioned rats, similarly as previously reported for isoflurane-induced preconditioning.
Thus, in summary, xenon-, anesthetic- and ischemic-induced preconditioning certainly share
mechanistic similarities, in particular in regard to signaling pathways, but they also exhibit
potentially significant differences in the triggering phase.
The current results should be interpreted within the constraints of several possible limitations.
Isolated mitochondria used for assessing mitochondrial function before and after hypoxia and
reoxygenation injury constitute an artificial system deprived of a normal cellular environment
that most certainly influences their function under control conditions. Nevertheless, this model
allowed us to address the question of whether the signaling pathways induce a “protective”
memory effect within mitochondria. The experiments were conducted in barbiturate-
anesthetized, acutely instrumented rats. Whether similar results also occur in other animal
species or humans is unknown. A xenon dose-response relationship was not examined with
the current investigation. Whether longer periods of xenon exposure produce relatively larger
reductions in infarct size, phosphorylation of Akt or GSK-3β, or protection against Ca2+-
induced mPTP opening will require additional study to ascertain. We did not measure further
variables of myocardial function, such as left ventricular developed pressure and left
ventricular end-diastolic pressure or cardiac output. In order to explain the observation that, in
spite of decreased infarct size in the xenon group, we did not find differences in mean arterial
blood pressure between control and xenon groups, we speculate that a decrease in cardiac
output was paralleled by an increase in systemic vascular resistance in the controls.
Sympathetic nerve activity is activated to compensate for an attenuation of contractility,
leading to tachycardia and increasing afterload. Myocardial infarct size is determined primarily
by the size of the area at risk and the extent of coronary collateral perfusion. The area at risk
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expressed as a percentage of total LV mass was similar between groups in the current
investigation, and coronary collateral blood flow is minimal in rats.39 Thus, differences in
collateral perfusion among groups probably did not account for the observed results in rats,
but coronary collateral blood flow was not specifically measured. Coronary venous oxygen
tension was not directly measured nor was myocardial oxygen consumption calculated. Rate-
pressure product, an index of myocardial oxygen consumption, was similar among groups
during coronary occlusion, suggesting that the ischemic burden was not responsible for
differences in infarct size in rats pretreated with xenon compared with those that did not receive
the noble gas. We used a 30 min LAD occlusion to produce myocardial infarction in rats.
Whether xenon produces cardioprotection after more prolonged periods of ischemia is
unknown.
In summary, the current results indicate that xenon preconditioning reduces myocardial infarct
size, phosphorylating Akt and GSK-3β, inhibiting Ca2+-induced opening of mPTP and
preserving mitochondrial function. The data suggest that xenon-induced cardioprotection
occurs as a consequence of activation of prosurvival signaling that targets mitochondria and
renders them less vulnerable to ischemia-reperfusion injury.
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Figure 1.
Schematic illustration of the experimental protocols used in the current investigation. Xe =
xenon; Wort = wortmannin.
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Figure 2.
Typical chart recordings showing respiration under baseline conditions and after hypoxic stress
in mitochondria isolated from control and xenon-preconditioned rats. Oxygen consumption
was initiated by addition of pyruvate/malate, accelerated by addition of adenosine diphosphate
(ADP) (state 3 respiration), and decelerated after all ADP was consumed (state 4 respiration).
After hypoxic stress, state 3 and state 4 respiration were preserved in xenon-preconditioned
mitochondria. Open circle = control; Solid circle = xenon preconditioning.
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Figure 3.
Effect of xenon preconditioning on isolated mitochondrial bioenergetics. Under baseline
conditions, no difference was detected in state 3 and 4 respiration of control and xenon-
preconditioned mitochondria. After exposure to hypoxic stress, state 3 respiration of
mitochondria from control rats was significantly decreased (Panel A). Respiratory control ratio
(RCR) of mitochondria from xenon-preconditioned rats was preserved after hypoxic stress, in
contrast to the findings in the absence of xenon (Panel B). CON = control; Xe = xenon
preconditioning (n = 7 per group). Values are mean ± SD. *Significantly (P < 0.05) different
from baseline.
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Figure 4.
Effect of xenon preconditioning on isolated mitochondrial permeability transition pore (mPTP)
opening. A typical chart recording showing mitochondrial membrane potential at state 2 with
increasing calcium concentration ([Ca2+]) is illustrated in Panel A. The arrows denote the
addition of Ca2+ in 5 μM increments. Depolarization was detectable by opening mPTP and
releasing Ca2+ from mitochondrial through the mPTP with sequential Ca2+ loading. Xenon
preconditioning delayed depolarization, indicating inhibition of mPTP opening. Open circle =
control; Solid circle = xenon preconditioning. Depolarization was not observed in the presence
of mPTP inhibitor cyclosporine A. Histograms summarizing the results are depicted in Panel
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B. CON = control; Xe = xenon preconditioning (n = 6 per group). Values are mean ± SD.
*Significantly (P < 0.05) different from CON.
Mio et al. Page 15
Anesth Analg. Author manuscript; available in PMC 2009 September 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
Xenon increased phosphorylation of Akt and glycogen synthase kinase 3 β (GSK-3β) in rat
ventricular myocardium. Western blots are shown using antiserum against phosphorylated Akt
at Ser 473 (p-Akt) and total Akt (Panel A), and against phosphorylated GSK-3β at Ser 9 (p-
GSK-3β) and total GSK-3β (Panel B). Histograms depict the relative density of p-Akt and p-
GSK-3β normalized to the total Akt and GSK-3β content, respectively (Panel C). CON =
control; Xe = xenon preconditioning (n = 4 per group). *Significantly (P < 0.05) different from
CON.
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Table 1
Hemodynamics During Infarct Size Experiments
Occlusion Reperfusion
Baseline 30 min 60 min 120 min
HR (bpm)
    Control 389 ± 30 370 ± 26 350 ± 17* 344 ± 18*
    Xenon 354 ± 34 325 ± 26† 286 ± 13*† 293 ± 23*†
    Control + Wort 370 ± 28 362 ± 28 323 ± 20* 334 ± 18*
    Xenon + Wort 368 ± 43 328 ± 14† 279 ± 28*† 303 ± 28*†
MAP (mm Hg)
    Control 113 ± 22 104 ± 24 82 ± 26* 72 ± 17*
    Xenon 121 ± 30 113 ± 10 81 ± 4* 74 ± 10*
    Control + Wort 115 ± 17 113 ± 13 86 ± 18* 76 ± 8*
    Xenon + Wort 120 ± 11 121 ± 21 87 ± 13* 82 ± 20*
RPP (mm · Hg min−1 · 10−3)
    Control 52.9 ± 12.8 45.0 ± 11.7 35.6 ± 6.8* 31.5 ± 7.0*
    Xenon 50.5 ± 10.4 41.9 ± 4.1 28.4 ± 2.6*† 28.2 ± 2.6*
    Control + Wort 52.6 ± 10.2 40.4 ± 8.0 32.1 ± 8.3* 27.8 ± 6.0*
    Xenon + Wort 51.3 ± 9.2 35.6 ± 12.4 28.7 ± 6.7* 28.8 ± 7.9*
Data are mean ± SD; n = 6 per group.
HR = heart rate; MAP = mean arterial blood pressure; RPP = rate pressure product; Wort = Wortmannin.
*
Significantly (P < 0.05) different from baseline.
†
Significantly (P < 0.05) different from control.
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